Illumina, Inc., a leading genomics company, announced the appointment of Dr. Eric D. Green, M.D., Ph.D., as Chief Medical Officer, effective February 2. Reporting directly to the CEO, Dr. Green will lead Illumina’s efforts to expand the clinical applications of genomics, improve access to precision medicine, and enhance the diversity of genomic data globally. He will serve as a scientific and medical leader for the company and will be part of Illumina’s Executive Leadership Team, helping guide the company’s strategy and technology roadmap while advancing its mission to improve human health through genomics.

Health Technology Insights: The Guthrie Clinic Announces New Chief Digital Officer

Jacob Thaysen, CEO of Illumina, stated that Dr. Green is a once-in-a-generation genomics leader whose decades-long career has shaped the field. He noted that Dr. Green’s experience building trust with scientific, clinical, and public health communities will be invaluable as Illumina works to broaden the impact of its genomic innovations worldwide. Dr. Green brings over thirty years of experience from the National Human Genome Research Institute at the U.S. National Institutes of Health, where he served as Director from 2009 to 2025 and played a key role in transforming genomics from a research-focused field into a cornerstone of modern medicine and public health.

Health Technology Insights: Rocket Doctor AI Partners to Boost AI Clinical Support in Alberta

Dr. Green said he is excited to join Illumina at a time when genomic information is becoming increasingly essential in clinical care. He emphasized that Illumina is central to the growing omics ecosystem and is uniquely positioned to shape the next phase of genomic medicine. Dr. Green trained as a physician scientist at Washington University School of Medicine, earning both an M.D. and Ph.D., and began his career in genomics during his residency in clinical pathology. He was a key participant in the Human Genome Project and has since become an internationally recognized leader in the field.

Illumina also announced that Everett Cunningham, the company’s Chief Commercial Officer, will depart to become CEO of a life science tools company. Jacob Thaysen thanked Mr. Cunningham for his leadership during a critical period of transition and confirmed that he will serve as interim Chief Commercial Officer until a permanent replacement is named. Illumina will participate in the upcoming J.P. Morgan Healthcare Conference, with CEO Jacob Thaysen scheduled to speak on Tuesday, January 13, at 7:30 AM Pacific Time.

Health Technology Insights: Amphista Reveals AMX-883 Preclinical Data for AML Therapy

To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com